Non Small Cell Lung Cancer (NSCLC)

Stage I-III, Resectable

Standard Risk

Scheduled for Resection

Tumor < 4 cm, No Clinical Nodes

LUN0101
Phase III
Chemotherapy +/- Pembrolizumab in Neoadjuvant/Adjuvant Tx Resectable Stage IIB / IIA NSCLC
PI: Wakelee
Sponsor: Merck Sharp & Dohme Corp.

LUN0099
Phase III
Panitumumab [RDye800 Optical Imaging Agent to Detect Lung Cancer During Surgery
PI: Lui
Stanford

ALK Mutation

ECOG4512
Phase III
Crizotinib vs Observation in NSCLC w/ Anaplastic Lymphoma Kinase (ALK) Fusion Protein Tumors
PI: Wakelee
ECOG-ACRIN

EGFR Mutation

ECOG481105
Phase III Erlotinib or Placebo in Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC
PI: Wakelee
ECOG-ACRIN

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold